Niagen Bioscience, Inc.

NasdaqCM:NAGE Stock Report

Market Cap: US$603.9m

Niagen Bioscience Management

Management criteria checks 4/4

Niagen Bioscience's CEO is Rob Fried, appointed in Jun 2018, has a tenure of 6.75 years. total yearly compensation is $1.16M, comprised of 43.1% salary and 56.9% bonuses, including company stock and options. directly owns 2.03% of the company’s shares, worth $12.25M. The average tenure of the management team and the board of directors is 5.1 years and 7.9 years respectively.

Key information

Rob Fried

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage43.1%
CEO tenure6.8yrs
CEO ownership2.0%
Management average tenure5.1yrs
Board average tenure7.9yrs

Recent management updates

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Recent updates

ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28
Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29
ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08
Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31
We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale

Oct 03

ChromaDex in pact to introduce anti-aging compound in Brazil

Sep 01

Ayana Bio appoints Frank Jaksch as CEO

Aug 24

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

CEO Compensation Analysis

How has Rob Fried's remuneration changed compared to Niagen Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

US$9m

Sep 30 2024n/an/a

US$1m

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$1mUS$500k

-US$5m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$500k

-US$17m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$27m

Dec 31 2021US$1mUS$500k

-US$27m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$1mUS$519k

-US$20m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$2mUS$487k

-US$32m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$33m

Mar 31 2019n/an/a

-US$33m

Dec 31 2018US$5mUS$379k

-US$33m

Compensation vs Market: Rob's total compensation ($USD1.16M) is below average for companies of similar size in the US market ($USD3.37M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Fried (64 yo)

6.8yrs

Tenure

US$1,160,206

Compensation

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of Niagen Bioscience, Inc. (formerly known as ChromaDex Corporation) since June 22, 2018 and its a Director since July 2015. Mr....

Leadership Team

NamePositionTenureCompensationOwnership
Frank Jaksch
Co-Founder & Chairman25.1yrsUS$92.31k2.98%
$ 18.0m
Robert Fried
CEO & Director6.8yrsUS$1.16m2.03%
$ 12.2m
Ozan Pamir
CFO & Principal Accounting Officerless than a yearno data0.0037%
$ 22.5k
Andrew Shao
Senior Vice President of Global Regulatory & Scientific Affairs5.1yrsno datano data
Carlos Lopez
Senior VP & General Counselless than a yearno data0.0029%
$ 17.5k
Michiko Kelley
Chief Marketing Officerless than a yearno datano data
Chu Yan
Managing Director of Asia Pacific6.4yrsno datano data
Kendall Knysch
Head of Media Relations & Partnershipsno datano datano data
James Lee
Controllerno datano datano data

5.1yrs

Average Tenure

52yo

Average Age

Experienced Management: NAGE's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frank Jaksch
Co-Founder & Chairman25.1yrsUS$92.31k2.98%
$ 18.0m
Robert Fried
CEO & Director9.7yrsUS$1.16m2.03%
$ 12.2m
Rudolph Emile Tanzi
Member of Scientific Advisory Board7.8yrsno datano data
Steven Rubin
Lead Independent Director8yrsUS$117.31k0.0090%
$ 54.2k
Roger Kornberg
Chairman of the Scientific Advisory Board10.7yrsno datano data
J. German
Member of Scientific Advisory Board10.5yrsno datano data
Ann Cohen
Independent Director2.9yrsUS$89.81k0%
$ 0
Wing Yu
Non-Executive Director7.6yrsUS$67.31k0%
$ 0
Kristin Patrick
Independent Director2.9yrsUS$82.31kno data
Charles Brenner
Chief Scientific Advisor & Member of Scientific Advisory Board10.5yrsno datano data
John Walker
Member of Scientific Advisory Board6.8yrsno datano data
Brunie Felding
Member of the Scientific Advisory Board5.7yrsno datano data

7.9yrs

Average Tenure

63yo

Average Age

Experienced Board: NAGE's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 22:03
End of Day Share Price 2025/03/24 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Niagen Bioscience, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey Van SinderenB. Riley Securities, Inc.
Robert WassermanDawson James Securities
Jeffrey MarkFarmhouse Equity Research